565-P: Baseline Findings from the Dulce Digital 2.0 Trial—Innovative Diabetes Self-Management in the Digital Age

Introduction: Telehealth delivery of diabetes self-management education and support (DSMES) has been widely adopted, yet lower participation is occurring in Hispanics who are disproportionately impacted by type 2 diabetes (T2D). Objective: Describe baseline and recruitment characteristics in an in-progress 3-way RCT that will compare the effectiveness of the Dulce Digital text messaging program and live in-person and virtual delivery (video telehealth classes) of Project Dulce DSMES in improving glycemic management of 150 Hispanic adults with T2D and A1C of ≥ 8%. Methods: Descriptives statistics. Results: There were 612 patients approached after EHR review. After recruitment screening, 69% did not meet the eligibility criteria, 8% were eligible and interested, and 24% were eligible but not interested. Reasons for disinterest were inconvenient class times (48%), concerns about study demands (e. g. , length of study; 23%), distrust in research or health professionals (20%), lack of access to study location (6%), and limited access/knowledge of technology (2%). Enrolled participants (n=46) were on average 55 ± 11. 3 years old, and 50% were female, 44% were born in the US, 70% had English as the preferred language, 54% were employed full-time, 49% had ≤ high school education, and 38% had an annual household income of ≥ 55K. Mean baseline A1C was 9. 5% ± 1. 5. Mean scores for Summary of Diabetes Self-Care Activities subscales were diet = 3. 8 ± 1. 9, exercise = 3. 2 ± 2. 4, glucose management = 3. 8±2. 6, and foot care = 3. 5 ± 2. 5 (range = 0-7) ; and Brief Measure of Healthy Literacy scale was 2. 4 ± 1. 5 (range = 0-10). Conclusion: The average baseline A1C was high while mean scores for self-care behaviors were low-to-moderate and low for health literacy. Healthcare systems should consider addressing multilevel barriers to in-person and telehealth DSMES delivery to enhance engagement and improve diabetes outcomes, especially in high-risk Hispanic adults with limited health literacy. Disclosure E. N. San Diego: None. M. Ruiz: None. N. Orendain: None. K. L. C. Millar: None. S. M. Saenz: None. J. De Jesus-Gonzalez: None. H. A. Shaikh: None. A. Philis-Tsimikas: Advisory Panel; Dexcom, Inc. , Lilly Diabetes, Novo Nordisk, Sanofi, Medtronic, Bayer Inc. Funding Merck (IIS#60691) ; National Institutes of Health (K12 TR004410) ; National Institutes of Health (KL2 TR001112) ; National Institutes of Health (P50MD017344)